<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8096">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01733004</url>
  </required_header>
  <id_info>
    <org_study_id>MM-141-01-01-01</org_study_id>
    <nct_id>NCT01733004</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a &quot;3+3&quot;
      design, evaluating MM-141 at varying dose levels and frequencies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Severity and number of adverse events related to escalating doses of MM-141</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the Phase II dose based either on the maximum tolerated dose (MTD) or recommended dose in patients with advanced solid malignancies.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-141 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-141 and Everolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-141 and Abraxane and Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-141</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced malignant solid tumors for which no curative therapy exists that has
             recurred or pgrogressed following standard therapy

          -  Eighteen years of age or above

          -  Able to understand and sign an informed consent (or have a legal representative who
             is able to do so)

          -  Measurable disease according to RECIST v1.1

          -  ECOG Performance Score of 0 or 1

          -  Adequate bone marrow, hepatic, renal and cardiac function

          -  Willing to abstain from sexual intercourse or to use an effective form of
             contraception during the study and for 90 days following the last dose of MM-141

        Exclusion Criteria:

          -  Active infection or fever &gt; 38.5°C during screening visits or on the first scheduled
             day of dosing

          -  Symptomatic CNS disease

          -  Received other recent antitumor therapy

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akos Czibere, MD, PhD</last_name>
    <phone>617-441-1000</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Moore, RHIT, CTR</last_name>
      <phone>770-496-9427</phone>
      <email>christopher.moore@gacancer.com</email>
    </contact>
    <investigator>
      <last_name>Mansoor Saleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Isakoff, MD, PhD</last_name>
      <phone>617-726-2000</phone>
    </contact>
    <investigator>
      <last_name>Steven Isakoff, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Forman, BAA, CCRP</last_name>
      <phone>313-576-8096</phone>
      <email>formank@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Patricia LoRusso, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Goustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Arnedos, MD</last_name>
      <phone>0033 1 42 11 40 68</phone>
      <email>monica.arnedos@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Charles Soria, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>November 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Oncology</keyword>
  <keyword>Phase I</keyword>
  <keyword>ErbB3</keyword>
  <keyword>IGF-1R</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Abraxane</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
